The Cass Review: findings and recommendations

What did the Cass Review find about youth gender medicine in England, and what did it recommend?

The Cass Review was commissioned by NHS England after serious concerns emerged about the capacity, clinical model and evidence base of the national service for children and young people presenting with gender-related distress. For many years, the Tavistock’s Gender Identity Development Service, usually known as GIDS, was the sole national NHS specialist service in England. Referrals rose sharply and the profile of those referred changed substantially, with a marked increase in adolescent girls and young people with complex mental-health, neurodevelopmental and safeguarding needs.

Background

The Cass Review was commissioned by NHS England after serious concerns emerged about the capacity, clinical model and evidence base of the national service for children and young people presenting with gender-related distress. For many years, the Tavistock’s Gender Identity Development Service, usually known as GIDS, was the sole national NHS specialist service in England. Referrals rose sharply and the profile of those referred changed substantially, with a marked increase in adolescent girls and young people with complex mental-health, neurodevelopmental and safeguarding needs.

Dr Hilary Cass, a former president of the Royal College of Paediatrics and Child Health, was asked to consider how services should be organised and what evidence supported available interventions. Her final report followed an interim report in February 2022, several University of York evidence reviews, research on international guidelines and extensive engagement with clinicians, families and young people (Cass Review, 2024).

The Review took place against the backdrop of litigation. In December 2020, the High Court in Bell v Tavistock issued a declaration concerning the information a child would need to understand to consent to puberty blockers. The Court of Appeal set that declaration aside in September 2021, holding that it was for clinicians, rather than the courts, to determine competence and consent case by case. The Supreme Court declined further appeal in April 2022. These judgments did not decide whether puberty blockers were clinically effective; the Cass Review was instead concerned with evidence, service design and patient safety.

What the documents say

Evidence and clinical uncertainty

The central finding was that the evidence base for paediatric gender medicine was weak. The Review stated that research on puberty blockers and masculinising or feminising hormones was generally of poor quality, often based on uncontrolled observational studies, short follow-up periods and incomplete information about longer-term outcomes. It found that claims about benefits and harms had frequently been overstated in public debate and, at times, in clinical discourse (Cass Review, 2024).

For puberty blockers, the Review concluded that the rationale for early suppression of puberty remained unclear. It found insufficient and inconsistent evidence that blockers improved gender dysphoria, mental health or psychosocial functioning. It also identified concerns about bone density and uncertainties about cognitive, psychosexual and wider physical development. The Review did not say that every young person given blockers had been harmed. It said that the available evidence was inadequate to establish a reliable balance of benefits and risks for this indication.

For masculinising and feminising hormones, the Review found similarly limited long-term evidence. It recommended “extreme caution” for 16- and 17-year-olds, a clear clinical rationale and discussion of cases in a national multidisciplinary team. It did not recommend routine hormone treatment for younger adolescents and stressed the importance of explaining implications for fertility, sexual function and lifelong treatment (Cass Review, 2024).

A different service model

The Review found that a single national specialist clinic was not an appropriate long-term model. It recommended regional NHS services linked to paediatric hospitals, supported by local multidisciplinary provision. Assessment was to be broader and more thorough, considering mental health, autism and other neurodevelopmental conditions, family circumstances, trauma, sexuality, physical health and safeguarding. Gender-related distress was not to be treated as an isolated issue detached from the rest of a young person’s life.

The Review also recommended better support while young people wait for specialist assessment. It called for psychological and psychosocial help, parent and carer support, clearer pathways into mental-health services, and better training for GPs, paediatricians, mental-health staff and other professionals. It further recommended services for people who stop, pause or reverse a medical transition, commonly described as detransitioners.

Social transition, data and research

Cass did not prescribe a single rule for social transition. However, it said that social transition should be treated in NHS settings as an active intervention rather than a neutral act, because it may affect psychological functioning and longer-term outcomes. For pre-pubertal children, it recommended that families should be able to obtain early advice from clinicians with relevant experience (Cass Review, 2024).

The Review repeatedly identified missing data as a major failure. It recommended a core national dataset, a data repository, outcome tracking and routine audit. It also called for a formal research programme, including a puberty-blocker study. The objective was not simply to collect more evidence in the abstract, but to make future care accountable to measurable outcomes.

On private provision, Cass warned of fragmented care and prescribing outside properly integrated NHS clinical oversight. It recommended that the Secretary of State consider statutory solutions to prevent inappropriate prescribing of puberty blockers and masculinising or feminising hormones to under-18s (Cass Review, 2024).

The positions

Supporters of the Review regard it as a necessary correction to a service culture in which medical pathways had developed faster than the evidence. They point to the independent evidence reviews, the absence of robust long-term outcome data and the Review’s emphasis on normal paediatric practice: careful diagnosis, differential assessment, family involvement, multidisciplinary decision-making and follow-up. NHS England accepted the need for a fundamentally different model and closed GIDS on 31 March 2024, with new regional services beginning from 1 April 2024 (NHS England, 2024).

Critics, including some trans advocacy groups, clinicians and academics, argue that the Review applied an excessively restrictive standard of evidence and discounted observational studies that are common in paediatric medicine. They contend that restricting access to medical treatment may increase distress for some young people and that the Review’s account of social transition and clinical outcomes is too cautious. The British Medical Association announced an evidence-led evaluation of the Review after internal disagreement in 2024 (BMA, 2024).

Both positions accept an important fact: many referred young people are distressed and need timely, competent care. The central disagreement is whether the uncertain evidence justifies a precautionary approach to medical intervention or whether restrictions themselves create unacceptable clinical risk.

Interpretation

Beyond Gender’s reading is that the Cass Review records a profound institutional failure. The problem was not that children with gender-related distress were seen by the NHS; they should be. The problem was that a vulnerable and clinically complex group was channelled towards interventions without the level of evidence, data collection, diagnostic discipline and long-term follow-up expected in other areas of paediatrics.

The Review does not support the claim that all gender distress is identical, that every young person will desist, or that medical intervention can never be appropriate. Its more important conclusion is narrower and more consequential: England did not possess a reliable evidence base for routine paediatric medical transition. In a system built around safeguarding and informed consent, that should have required caution from the outset.

The change in NHS policy on puberty blockers preceded the final report but was consistent with the evidence concerns Cass later set out. The later restrictions on private supply were a government response to the risks of an NHS policy being bypassed through fragmented and inadequately supervised prescribing. Those restrictions are not themselves identical to the Cass recommendations, but they follow the Review’s concern about unsafe or disconnected care.

Open questions

The largest unanswered question is whether England will now produce the long-term, independently audited evidence that was missing during the Tavistock era. That requires not only trials or research protocols but also transparent data on mental health, physical health, fertility counselling, sexual function, treatment discontinuation, regret, detransition and adult outcomes.

There are also practical questions about access. A more cautious model must not become a model of neglect. Children and adolescents experiencing distress need prompt assessment, treatment for co-occurring anxiety, depression, trauma or neurodevelopmental difficulties, and support for families. Long waits are not evidence-based care.

Finally, the relationship between health services, schools and parents remains unsettled. The Cass Review was principally a review of NHS clinical services, not a schools policy. Yet its findings on social transition, family involvement and the need for caution have clear implications for safeguarding decisions outside clinics. The test for institutions should be whether they are helping children to explore distress safely, rather than assuming in advance that a particular identity or medical outcome is inevitable.

On the UK timeline

Episodes on this subject

Inside Europe's Transgender Medicine System with Róisín Michaux

Rethinking Youth Gender Medicine with Dr Louise Irvine

The Doctors Transitioned My Son at 13 - Here’s What Happened Next...